Higher serum nitrate levels are associated with poor survival in lung cancer patients

被引:18
作者
Colakogullari, Mukaddes
Ulukaya, Engin [1 ]
Yilmaztepe, Arzu
Ocakoglu, Gokhan
Yilmaz, Meryem
Karadag, Mehmet
Tokullugil, Asuman
机构
[1] Uludag Univ Tip Fak, Dept Biochem, TR-16059 Gorukle, Turkey
[2] Uludag Univ, Fac Med, Dept Biostat, Gorukle, Turkey
[3] Uludag Univ, Fac Med, Dept Chest Dis & TB, Gorukle, Turkey
关键词
nitric oxide (NO); vascular endothelial growth factor-A (VEGF-A); lung cancer; survival; serum nitrite/nitrate;
D O I
10.1016/j.clinbiochem.2006.06.008
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: Angiogenic factors induce tumour growth and angiogenesis which leads to tumour metastasis and a poor survival rate. This study aimed to assess the possible roles of nitric oxide (NO) and vascular endothelial growth factor-A (VEGF-A) in the overall survival of patients with late stage lung cancer. Design and methods: The study was carried out with primary lung carcinoma patients (n = 31) and healthy controls (n = 15). Pre- and post-cisplatin-based chemotherapy serum nitrite/nitrate levels were measured as nitrite after enzymatic conversion followed by Griess reaction and serum VEGF-A analysis was performed using ELISA. After patient follow-up, survival rates were calculated by using the Kaplan-Meier method [Dudek et al. Cancer Invest 2005; 23(3):193-200]. Results: The serum nitrite/nitrate and VEGF-A levels of lung cancer patients and the control group were 93.7 +/- 48.9 and 63.7 +/- 32.2 PM (p=0.018), and 620 +/- 491 and 255 +/- 157 pg/mL (p = 0.001), respectively, High nitrite/nitrate (> 67.2 mu M) concentration had statistically significant effects on overall survival (Cox analysis, p = 0.026). The overall survival of the lung cancer patients with higher serum nitrate concentrations was significantly less than the ones with lower serum nitrite/nitrate (Kaplan-Meier survival functions test, log rank significance = 0.0007). Conclusion: Our results suggest that having a high serum nitrite/nitrate concentration is a strong indicator of poor survival for late stage lung cancer patients. However, this conclusion deserves to be elucidated further by using a larger sample size. (c) 2006 The Canadian Society of Clinical Chemists. All rights reserved.
引用
收藏
页码:898 / 903
页数:6
相关论文
共 39 条
[21]  
Kimura H, 2003, ACTA BIOCHIM POL, V50, P49
[22]  
Kisley LR, 2002, CANCER RES, V62, P6850
[23]   Circulating angiogenesis regulators in cancer patients [J].
Kuroi, K ;
Toi, M .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2001, 16 (01) :5-26
[24]   Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer [J].
Laack, E ;
Köhler, A ;
Kugler, C ;
Dierlamm, T ;
Knuffmann, C ;
Vohwinkel, G ;
Niestroy, A ;
Dahlmann, N ;
Peters, A ;
Berger, J ;
Fiedler, W ;
Hossfeld, DK .
ANNALS OF ONCOLOGY, 2002, 13 (10) :1550-1557
[25]  
Marrogi AJ, 2000, CLIN CANCER RES, V6, P4739
[26]   Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer [J].
Matsuyama, W ;
Hashiguchi, T ;
Mizoguchi, A ;
Iwami, F ;
Kawabata, M ;
Arimura, K ;
Osame, M .
CHEST, 2000, 118 (04) :948-951
[27]  
MOSHAGE H, 1995, CLIN CHEM, V41, P892
[28]   Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis [J].
Niklinska, W ;
Burzykowski, T ;
Chyczewski, L ;
Niklinski, J .
LUNG CANCER, 2001, 34 :S59-S64
[29]   Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma [J].
Poon, RTP ;
Ng, IOL ;
Lau, C ;
Yu, WC ;
Fan, ST ;
Wong, J .
AMERICAN JOURNAL OF SURGERY, 2001, 182 (03) :298-304
[30]   High expression of nitric oxide synthases is a favorable prognostic sign in non-small cell lung carcinoma [J].
Puhakka, A ;
Kinnula, V ;
Näpänkangas, U ;
Säily, M ;
Koistinen, P ;
Pääkkö, P ;
Soini, Y .
APMIS, 2003, 111 (12) :1137-1146